含姜黄素纳米胶束作为COVID-19辅助治疗的随机对照试验方案结构化摘要
本研究为前瞻性、安慰剂对照、平行组、单中心随机临床试验,计划纳入40例COVID-19患者,评估含姜黄素纳米胶束作为辅助治疗对免疫应答平衡的影响。干预组在常规治疗基础上加用40mg姜黄素纳米胶束胶囊每日四次,对照组使用外观相同的安慰剂,疗程两周。主要结局包括临床症状、实验室指标及Th1/Th2/Treg/Th17相关细胞因子和基因表达变化。
要点
- 姜黄素纳米胶束作为COVID-19辅助治疗,每日40mg四次,疗程两周。
- 主要评估免疫平衡:IFN-γ、IL-17、IL-4、TGF-β及T-bet、GATA-3、FoxP3、ROR-γT。
- 随机双盲安慰剂对照,计划入组40例,1:1分配。
核心结论
- 该研究旨在评估含姜黄素纳米胶束作为COVID-19辅助治疗对免疫应答平衡的调节作用,目前仅为试验方案摘要。
研究设计与样本
- 前瞻性、安慰剂对照、平行组、单中心随机临床试验,计划纳入40例COVID-19患者,1:1随机分配至干预组和安慰剂组。
- 随机化采用计算机生成的随机数字和密封编码盒,对患者、医师、护士、实验室技术人员和统计师设盲。
关键数值与推荐
- 干预组在常规标准治疗基础上给予40mg含姜黄素纳米胶束胶囊,每日四次(早、午、晚餐后及睡前),疗程两周;对照组给予外观相同的安慰剂胶囊。
- 主要结局包括第0、7、14天的临床症状和实验室指标(如炎症标志物),以及血清IFN-γ、IL-17、IL-4、TGF-β水平和T-bet、GATA-3、FoxP3、ROR-γT基因表达。
- 纳入标准:实时PCR确诊COVID-19、年龄18-75岁、签署书面知情同意、未参与其他临床试验。
- 排除标准包括妊娠或哺乳、对姜黄或姜黄素过敏、吸烟、使用呼吸机、SaO2低于90%或PaO2低于8 kPa、严重合并症(如肾衰竭、肝衰竭、心力衰竭、COPD)、胆结石史、胃炎或活动性胃溃疡史。
局限性
- 本文仅为研究方案摘要,尚未报告研究结果。
- 样本量较小(40例),单中心设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigates the effectiveness of curcumin-containing Nanomicelles as a therapeutic supplement in the treatment of patients with COVID-19 and its effect on immune responses balance changes following treatment. TRIAL DESIGN: This study is conducted as a prospective, placebo-controlled with parallel group, single-center randomized clinical trial on COVID-19 patients. PARTICIPANTS: Patients are selected from the COVID-19 ward of Shahid Mohammadi Hospital in Bandar Abbas, Iran. INCLUSION CRITERIA: 1. Real time PCR-approved positive COVID-19 test. 2. Both gender 3. Age between 18 and 75 years 4. Signing a written consent 5. Lack of participation in other clinical trials Exclusion criteria: 1. Pregnancy or lactation 2. Allergy to turmeric or curcumin 3. Smoking 4. Patient connected to the ventilator 5. SaO2 less than 90% or PaO2 less than 8 kPa 6. Having comorbidities (such as severe renal failure, Glomerular filtration rate less than 30 ml/min, liver failure, Congestive heart failure, or Chronic obstructive pulmonary disease) 7. History of gallstones 8. History of gastritis or active gastrointestinal ulcer INTERVENTION AND COMPARATOR: In addition to the routine standard treatments for COVID-19, in the intervention group, 40mg nanomicelles containing curcumin (SinaCurcumin Capsule, Exir Nano Sina Company, Iran), four times per day (after breakfast, lunch, dinner and before bedtime) and in the placebo group as the control group, capsules with the same appearance and characteristics (Placebo capsules, Exir Nano Sina Company, Iran) are prescribed for two weeks. MAIN OUTCOMES: The effectiveness of Nano micelles containing curcumin treatment will be evaluated as daily clinical examinations of patients in both groups and, on days 0, 7 and 14, complete clinical symptoms and laboratory findings including peripheral blood and serum parameters such as inflammatory markers will be measured and recorded. Moreover, in order to evaluate the balance of immune responses changes following treatments, serum level of IFN-γ, IL-17, Il-4 and TGF-β serum cytokines will be measured in both groups at time points of 0, 7 and 14 days post treatment. Gene expression of t-bet, GATA-3, FoxP3 and ROR- γT will also be measured at mentioned time points to assess the shift of T helper1, T helper2, T regulatory and T helper 17 immune responses following treatment. RANDOMISATION: Randomized trials will be performed on 40 COVID-19 patients which will be randomized using encoded sealed boxes with computer generated random digits with 1:1 allocation ratio. In order to randomization, placebo and SinaCurcumin Capsules will be numbered first by computer generated random digits. SinaCurcumin and placebo will then be stored and numbered in sealed packages based on generated random numbers. Finally, according to the order in which patients enter the study, packages are given to patients based on their number. BLINDING (MASKING): The present study will be blind for all patients, physicians and nurses, laboratory technicians and statisticians. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): A total of 40 patients will be included in the study, 20 of them will be randomly assigned to the intervention group and 20 to the placebo group. TRIAL STATUS: This is Version 1.0 of protocol dated 21 May 2020. The recruitment was started June 24, 2020 and is expected to be completed by October 31, 2020. TRIAL REGISTRATION: This present clinical trial has been registered in the Iranian Registry of Clinical Trials (IRCT) with the registration code of "IRCT20200611047735N1", https://www.irct.ir/trial/48843 . Dated: 19 June 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
引用
- Hassaniazad M, Inchehsablagh BR, Kamali H, et al. The clinical effect of Nano micelles containing curcumin as a therapeutic supplement in patients with COVID-19 and the immune responses balance changes following treatment: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 33092653. doi:10.1186/s13063-020-04824-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。